Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis

Hooij, Anouk van; Boeters, Debbie M.; Fat, Elisa M. Tjon Kon; Eeden, Susan J. F. van den; Corstjens, Paul L. A. M.; Mil, Annette H M van der Helm-van; Geluk, Annemieke

doi:10.1128/cvi.00060-17

Cited by 16 publications

(12 citation statements)

References 39 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A decline in CXCL10 over time has been found in patients with RA that achieve DMARD-free sustained remission and in children with type 1 diabetes. 19,20 CXCL10 is also inversely correlated with PsA disease duration and declines in patients that have long-lasting PsA. 21,22 In our patient cohort, after diagnosis of PsA, CXCL10 continued to decline in converters only.…”

Section: Discussionmentioning

confidence: 63%

Declining levels of serum chemokine (C‐X‐C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*

et al. 2020

View full text Add to dashboard Cite

Summary Background We previously found that serum levels of chemokine (C‐X‐C motif) ligand 10 (CXCL10) decreased after the onset of psoriatic arthritis (PsA). Objectives We measured CXCL10 levels over time in patients with psoriasis who developed PsA to determine whether the drop in CXCL10 was specific to these patients and further assess its association with PsA development. Methods Prospectively followed patients with psoriasis without arthritis [cutaneous psoriasis (PsC)] were assessed yearly by rheumatologists for the presence of PsA. Patients with PsC who developed PsA (converters) were matched to those that did not develop PsA (nonconverters) based on psoriasis duration and the interval between follow‐up visits. The duration between baseline and the first visit postconversion in converters was used to assign a pseudoconversion date in nonconverters. Linear mixed‐effects models were used to model the expression of CXCL10 over time. Results CXCL10 significantly declined over time in converters prior to PsA development with a significant difference in the trend over time between converters (n = 29) and nonconverters (n = 52; P < 0·001). CXCL10 continued to decline after PsA onset in a subset of converters. There was a significant difference in the trend of CXCL10 levels between converters (n = 24) and nonconverters (n = 16; P = 0·01) preconversion/pseudoconversion. This difference remained postconversion (P = 0·006) and was not different from the preconversion period (P = 0·75). Conclusions A large difference in CXCL10 was identified in patients with PsC that are destined to develop PsA over time. This exploratory analysis supports the association of CXCL10 with PsA development in patients with PsC and warrants further study of the predictive ability of this chemokine. What is already known about this topic? Chemokine (C‐X‐C motif) ligand 10 (CXCL10) is elevated in psoriatic affected tissues and serum and/or plasma. Patients with psoriasis that develop psoriatic arthritis (PsA) have elevated CXCL10 levels at baseline and these levels drop after arthritis onset. What does this study add? By monitoring levels of CXCL10 in serum over multiple visits in patients with psoriasis that develop PsA as well as those that do not develop PsA, an association was identified between CXCL10 and PsA development. What is the translational message? CXCL10 is a strong candidate for use by physicians for the detection of patients with psoriasis that are at risk of developing PsA. Linked Comment: Kirby and Fitzgerald. Br J Dermatol 2020; 183:805–806.

show abstract

Section: Discussionmentioning

confidence: 63%

Declining levels of serum chemokine (C‐X‐C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Another study reported that there is a strong association between serum CXCL10 and disease activity scores (DAS) indicating that this chemokine can be a possible biomarker and diagnostic aid in monitoring disease progression in RA patients. 59 CXCR3 is expressed primarily on NK cells 60 and activated T lymphocytes especially the inflammatory Th1 cells, that secrete high levels of IFN-gamma. 60,61 It has been stated that CXCR3 knockout mice would be more resistant to inflammatory autoimmune diseases.…”

Section: Chemokines In Rheumatoid Arthritismentioning

confidence: 99%

<p>Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis</p>

Elemam¹,

Hannawi

Maghazachi³

2020

ITT

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases and a prototypic inflammatory disease, affecting the small joints of the hands and feet. Chemokines and chemokine receptors play a critical role in RA pathogenesis via immune cells recruitment. Several chemokines and chemokine receptors are abundant in the peripheral blood and in the local inflamed joints of RA. Furthermore, synthetic and biologics disease modifying anti rheumatic drugs have been reported to affect chemokines expression. Thus, many studies have focused on targeting chemokines and chemokine receptors, where some have shown positive promising results. However, most of the chemokine blockers in human trials of RA treatment displayed some failures that can be attributed to several reasons in their structures and binding affinities. Nevertheless, targeting chemokines will continue to be under development, in order to improve their therapeutic potentials in RA and other autoimmune diseases. In this review we provide an up-to-date knowledge regarding the role of chemokines and chemokine receptors in RA with an emphasis on their activities on immune cells. We also discussed the effects of drugs targeting those molecules in RA. This knowledge might provide impetus for developing new therapeutic modalities to treat this chronic disease.

show abstract

“…High levels of IP-10 are observed in a variety of inflammatory diseases and conditions 56–58 . We found markedly increasing IP-10 levels towards the end of treatment despite clinical improvement in four patients.…”

Section: Discussionmentioning

confidence: 99%

IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting

Hoel

Jørstad

Marijani³

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Treatment efficacy is difficult to evaluate in extrapulmonary tuberculosis (EPTB) patients. Interferon-γ inducible protein (IP-)10 has been suggested as a biomarker for response to treatment. We have investigated if IP-10 from dried plasma spots (DPS) or dried blood spots (DBS) can be used in treatment monitoring of EPTB patients in a low-resource setting of Zanzibar. IP-10 levels in plasma, DPS and DBS samples collected before, during (2 months) and after TB treatment of 36 EPTB patients (6 culture and/or Xpert MTB/RIF positive and 30 clinically diagnosed) and 8 pulmonary tuberculosis (PTB) patients, were quantified by an enzyme-linked immunosorbent assay. There was a high positive correlation between IP-10 measured in plasma and DPS and DBS, respectively. We found a significant decline in IP-10 levels from baseline to end of treatment in plasma, DPS and DBS, both in EPTB and PTB patients. The declines were observed already after 2 months in HIV negative patients. In conclusion, the DPS/DBS IP-10 assay allows for easy and manageable monitoring in low-resource settings and our findings suggest that IP-10 may serve as a biomarker for treatment efficacy in EPTB patients, albeit further studies in cohorts of patients with treatment failure and relapse are needed.

show abstract

Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis

Abstract: Although rheumatoid arthritis (RA)

Cited by 16 publications

References 39 publications

Declining levels of serum chemokine (C‐X‐C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*

Declining levels of serum chemokine (C‐X‐C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*

<p>Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis</p>

IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting

Contact Info

Product

Resources

About